Table 10: Results at Week 26 in a Trial Comparing TRESIBA U-200 to Insulin Glargine U-100 in Adult Patients with Type 2 Diabetes Mellitus on OAD(s)* Study F: TRESIBA Administered at the Same Time Each Day in Insulin Nave Adult Patients as an Add-on to One or More of the Following Oral Agents: Metformin, Sulfonylurea, Glinides or Alpha-Glucosidase Inhibitors The efficacy of TRESIBA was evaluated in a 26-week randomized, open-label, multicenter trial in Asia in 435 insulin nave patients with type 2 diabetes mellitus inadequately controlled on one or more oral antidiabetic agents (OADs) at baseline
Since it is a natural detoxifier, it improves the health of the bodys cells to reverse ageing
When thyroid hormone is low, or when conversion from T4 to the active T3 is impaired, patients often experience weight gain, fatigue, cold intolerance, and difficulty building or maintaining lean muscle despite appropriate nutrition and exercise
Potential fit: People who have experienced strong side-effects at standard starting doses and want a gentler acclimation
This flexibility allows patients to keep their current pen at room temperature during their active treatment week without compromising the medication's stability or effectiveness
Aim for 79 hours of quality sleep nightly
